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Abstract 
Transdermal drug delivery has been growing extensively in the past decades, therefore new, reliable and 
cost-effective in vitro models were demanded to support the research and development on this field. 
Model membrane of PAMPA, which can mimic skin penetration, was first described in 2006, but the need 
for a more bio-mimetic system has been arisen by new industrial tendencies and a bio-relevant system 
was published in 2012. Since its first publication, Skin PAMPA has already been applied by several 
universities and industrial groups successfully, and the first articles, podium and poster presentations 
have been appeared. The original Skin PAMPA model has been further developed in order to extend its 
application for formulations. Examples of liquid or semi-solid formulation projects and transdermal 
patch studies are available beside standard solution applications. The present review demonstrates the 
different approaches needed for various type of samples, provides examples of applications and 
practical conclusions for further improvement. 
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Introduction 
Estimation of skin penetration of compounds has become crucial in the past decades, as the advantages 
of dermal usage and transdermal absorption route have been recognized by many pharmaceutical and 
cosmetic companies [1]. It is common that the best estimation is provided by in vivo human skin studies, 
however its availability and the ethical regulation make it impossible to apply routinely in product 
development. In vitro human skin experiments could be the most useful replacement to predict human in 
vivo environment, but accessibility is difficult, especially for cosmetic industry. Therefore researchers 
started to work on development of artificial membrane models that can mimic the features of skin, while 
having much better availability and being more cost effective. Depending on the need, silicon based 
membranes, cellulose acetate or cellulose nitrate filters are available for Franz diffusion cell method; 
however these models have limited quality of prediction, suffer from poor standardization and do not even 
meet the high throughput criteria, that would be useful in early stages of discovery and development [2]. 
The current review introduces the PAMPA method and the Skin PAMPA model, that provides a good 
estimation of skin penetration, does not suffer from pure standardization and reproducibility, while having 
a high throughput and low cost option [3]. 
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With the introduction of the Biopharmaceutics Classification System [4], fast and reliable permeability 
measurement strategies were needed to classify the molecules at the earliest stages of discovery. In 1998, 
Kansy and co-workers have introduced the Parallel Artificial Membrane Permeability Assay (PAMPA) as a 
tool for rapid determination of passive membrane permeability of drugs [5]. The interest of the industry 
was growing extensively in the first decade of the method, mostly because of the method’s low cost and 
high throughput performance. Since the first publication by Kansy and co-workers, several companies have 
developed their own variants and many articles were published, indicating that PAMPA is a good research 
tool for physico-chemical property screening in early discovery stage [6]. PAMPA models have been 
published for the prediction of gastrointestinal absorption (GIT) [7,8] and for modelling the blood brain 
barrier (BBB) [9]. There are two models available for the estimation of skin penetration as well. 
The first PAMPA model for skin penetration estimation was published by Ottaviani et al. in 2006 [10]. 
This approach incorporates silicone oil and isopropyl myristate as membrane components, which are not 
the natural elements of the in vivo barrier. Also, that model was developed based on the Flynn database 
that contains human skin permeability results collected from many research groups using diverse 
experimental conditions. As it was shown in several studies [11-13], the difference between permeability 
data measured in various laboratories can exceed by an order of magnitude, therefore the prediction 
potential of this model is not proved yet. 
Following the tendencies of model development in pharmaceutical industry, Skin PAMPA was designed 
to be bio-mimetic, i.e. the same or similar components have been applied as present in the most important 
barrier of human skin [3]. As the main barrier of human skin, it is known to be the outermost layer of 
epidermis, the Stratum Corneum (SC), Skin PAMPA has been designed to mimic the features of this layer. 
SC composes of corneocytes embedded into a multilamellar lipid layer. Lipid layer consists of a mixture of 
ceramides, cholesterol and free fatty acids as major components, and provides the main route of 
penetration, the paracellular pathway [1]. Skin PAMPA membrane was created by using cholesterol, free 
fatty acid and a ceramide-analog compound that mimics the features of ceramides in the lipid matrix [14]. 
The ceramide-analogue compound (certramide) has been studied extensively and its properties have been 
found to be suitable for PAMPA membrane [15]. 
During the 15 years history of PAMPA, researchers have used the system to predict the permeability of 
compounds through the GIT, BBB or later through Skin. In most cases, the main goal was to determine 
permeability as kinetic parameter of pure compounds in early stage of drug discovery without any 
formulation effect. Most of the protocols was developed to satisfy this need, therefore buffer solutions at 
various pH with 0.5-1(-5) % DMSO was studied as donor solution and pure pH = 7.4 buffer as acceptor 
solution [16]. Donor concentration was selected according to the physico-chemical (solubility, pKa, logP) 
parameters of the compounds and permeability was calculated as the main parameter for comparison.  
Upon the expanding application of Skin PAMPA, an urgent need has been arisen for the investigation of 
drug formulations, including semi-solid dosage forms and transdermal patches. The following paragraphs 
describe the application possibilities of Skin PAMPA, provide some general considerations of assay design 
and data processing, and demonstrate some recent examples. 
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Applications 
Permeability studies of compounds in solution 
Samples of compounds dissolved in pure solvent or solvent mixture are typically applied in Skin PAMPA, 
when the permeation properties of active pharmaceutical ingredients (API) are investigated.  In these 
studies, the performance of the API itself is important, without any penetration enhancing or controlling 
effect. Simple solvents, like water based buffers, PEG 400, ethanol or propylene-glycol are applied in these 
projects that have a well-defined and usually predictable effect on permeability. The protocol of these 
studies is the same or similar to general PAMPA protocols, i.e. the concentration and the applied dose are 
selected based on the physico-chemical parameters of the API and not based on the relevant in vivo dose. 
The donor volume/membrane area ratio is also significantly higher compared to in vivo environment. 
Permeability is determined and used for assay evaluation, that is normalized for donor concentration, for 
surface area and for time, therefore it is capable to rank the compounds own permeation property.  
The performance of Skin PAMPA for API characterisation was first investigated by the inventors of the 
model. Two correlations were described and both were established as a result of careful human 
permeability data selection. Selection of appropriate, reliable reference dataset has fundamental 
importance in model validation, since several published databases contain results of different laboratories 
that can reduce the significance of the correlation. 
The first selected dataset was published by Lee and co-workers in 2010 [17]. This dataset provided 
homogenous and normalized permeability data for more than 40 compounds. The results were measured 
on dermatomed human female back skin using Franz diffusion cell method. 45 % PEG 400 was added to 
donor solution to mimic the effect of a basic formulation and pH was selected to be 6.4. The Skin PAMPA 
experiment for 15 compounds was performed with similar parameters to Franz cell experiment. 
Permeability was calculated and used for the comparison as the performance of the APIs. High correlation 
(R2= 0.84) was found between human skin data and Skin PAMPA data as shown on Figure 1. The good 
correlation also indicates good ranking order of compounds, so the model was able to characterize the 
permeability and rank the APIs properly. The authors have also compared Skin PAMPA results measured 
with pure buffer solutions in the donor phase to the same dataset, and found a significantly weaker 
correlation that indicates the responsiveness of the system for the simple formulation effects of PEG 400. 
The second database was the Full Validated dataset published by Hadgraft and Guy [18]. This database 
contains results measured in different laboratories and despite the careful validation criteria of selection 
the experimental conditions are very different. Therefore data were divided into small homogenous 
groups. Data were sorted based on the incubation temperature and the skin derivative used for the test. 
Skin PAMPA experiment was performed with the standard solution protocol, pure buffers solutions with 
1 % DMSO were studied as donor phase, pure buffer at pH = 7.4 was used as acceptor, and permeability 
was calculated for the correlation study.  Four comparisons were published and good correlation was 
found, however statistical evaluation was not possible for the reason of low number of compounds. A 
united correlation study performed on the published 4 small groups is shown on Figure 2. The obtained  
R2 = 0.70 value is also an acceptable correlation regardless of the uncertainty caused by the human data. 
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Figure 1. Comparison of human skin permeability data measured by Franz cell vs Skin PAMPA data. 
 
 
Figure 2. Correlation between human skin permeability data of Full Validated dataset and Skin PAMPA data. 
 
Karadzovska and Riviere published a study of 96 well based skin penetration models in 2013 that 
included Skin PAMPA as well, beside the other, previously mentioned PAMPA skin model by Ottaviani and 
Strat-M membrane of Merck [19]. Six compounds dissolved in three different solvents (water, ethanol and 
propylene-glycol) were studied. Compounds were applied in both saturated and unsaturated solutions, but 
both applications can be considered as infinite for the reason of the total applied dose. Permeability was 
calculated and used for the correlation study. The assays with saturated solutions were not successful, but 
the results of unsaturated solutions were in good agreement with data measured on human skin. They 
investigated the membrane retention of 96 well plate based models, and found good correlation to skin 
retention as well, therefore, all three models were found to be useful for transdermal penetration 
prediction. Skin PAMPA has been acknowledged as the most bio-mimetic membrane model, where specific 
skin mimetic interactions are more probable. 
In a paper published in 2013, Vizserálek and co-workers investigated the effect of incubation 
temperature on permeability using Skin PAMPA model among others [20]. The study concluded that Skin 
PAMPA results are more sensitive for incubation temperature compared to other, mostly phospholipid-
based PAMPA models. Figure 3 demonstrates the temperature dependence of 7 compounds. As the slope 
of the lines indicates, as high as 0.35 log unit difference can occur by performing the assay either at 25 or 
32 °C. Therefore, the authors concluded that proper incubation temperature is important for Skin PAMPA 
ADMET & DMPK 2(4) (2014) 191-198 SKIN PAMPA 
doi: 10.5599/admet.2.4.150 195 
assay, especially when formulations are investigated where the sample itself can have temperature 
dependent behavior. 
 
Figure 3. Temperature dependence of permeability in Skin PAMPA method. 
 
Permeability studies with liquid or semi-solid formulations 
Formulations require different approach compared to standard PAMPA application, as the aim of the 
study is to investigate the performance of the formulation, and not just the pure API. The modification 
affects the applied dose, the way of application and the calculated parameters as well. 
As the goal is to investigate the performance of the formulation, keeping the applied dose close to in 
vivo environment would provide more reliable information. The previously described general PAMPA 
protocol or Skin PAMPA protocol for solutions apply “infinite dosing”, that means significantly higher dose 
compared to in vivo case. Therefore, the dose should be reduced as much as possible to approach the 
“finite dosing”, i.e. the in vivo relevant amount [21]. The currently available protocols and plates make it 
possible to apply 10 times finite dose, that is much closer to finite situation than standard PAMPA assay, 
and the development of lower dose applications are still in process. New bottom plate (Formulation plate) 
has also been developed by the manufacturer to make the ‘10 times finite dose’ application possible. 
As the performance of the formulation as a complex matrix is investigated, parameters like flux, 
concentration in the receiver solution or permeated amount of drug are calculated, that are not normalized 
for the applied dose. These parameters are suitable for direct comparison of the formulations. It is 
advantageous if the permeation is studied in wider time period, and the permeated amount vs time profile 
is used for evaluation. This graph includes all the main information like permeated amount at certain time 
point, flux and lag time. 
As these considerations are the result of the latest developments, most of the cited studies below have 
not been designed according to all of these recommendations. 
On a poster of Clough and co-workers published at AAPS in 2013, the permeability enhancing effect of a 
series of solvents, lipidic fluids and emulsifiers were investigated [22]. Infinite dosing approach was 
followed by the authors and standard PAMPA sandwiches were used for the study. All samples contained 
5 % Ibuprofen-Na as API and 8 % of one of the investigated component beside water. The samples of lipidic 
fluids contained 45 % PEG 400 as well. Figure 4 demonstrates the receiver concentration after one hour of 
incubation where the authors have found significant differences in the permeability of Ibuprofen depending 
on the penetration enhancer. Unfortunately, correlation with human skin data is not available, but the 
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results itself suggest that the model is able to differentiate the samples, and therefore can be used for 
ranking the formulations. 
 
Figure 4. Permeability enhancing effect of different solvents, lipidic fluids and emulsifiers in case of ibuprofen 
measured by Skin PAMPA method [22]. 
 
Tsinman and co-workers presented their work with semi-solid formulation of ibuprofen at AAPS in 2012 
[23]. Three formulations and one slurry of ibuprofen were investigated using both Skin PAMPA model and 
real human skin mounted in Franz cell system. They have applied 30 µg formulation/well that is equal to ’10 
times finite dose application’ as mentioned before, and they used the receiver concentration for the 
comparison. Good agreement was found between Franz cell and Skin PAMPA results in terms of ranking 
order the samples, however Skin PAMPA model provided higher permeation results compared to human 
skin data. 
In 2014 at AAPS conference, Luo and co-workers  presented a comparison of Skin PAMPA results to 
porcine skin results measured with Franz cell method [24]. The study investigated the permeation of 3 APIs 
(ibuprofen, caffeine, uvinul A plus) using saturated solutions. They presented both infinite and ‘10 time 
finite’ dosing studies and used the cumulative permeated amount vs time profiles for data interpretation 
and analysis. The comparison shows, that Skin PAMPA can provide an excellent ranking order of samples, 
while having the advantage of much lower cost and ease of standardization. 
Permeability studies with transdermal patches 
Similarly to formulation studies, the aim of transdermal patch testing is to evaluate the performance of 
the patch as transdermal therapeutic system and not just the API, therefore similar approach is needed. The 
dosing is easier in this case as the patch is applied directly on the membrane without any need for normal 
or modified bottom plate, so the applied dose is predefined by the patch. As a significant amount of 
available patches must not be cut into pieces, it is recommended to apply them as they are. This application 
involves the occurrence of “edge effect” [25], which means a possible lateral diffusion of API within the 
adhesive layer that can increase the flux. 
It is recommended to determine the cumulative permeated amount vs time profile that can provide all 
the necessary information for comparison as detailed before. As most of the transdermal patches are 
designed to provide a zero order kinetic release of API, it is suggested to continue the Skin PAMPA study till 
the end of the proposed application period of the patch. 
The first and only study of transdermal therapeutic systems has been presented by Vizserálek and co-
workers at AAPS 2014 [26]. Transdermal patches of four APIs (nicotine, fentanyl, ketoprofen, rivastigmine) 
were applied on Skin PAMPA model. Figure 5 demonstrates the permeated amount vs time profile for 
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fentanyl as an example. The blue dashed line shows the in vivo delivery rate calculated from human blood 
level, while the red dots and black solid line demonstrate the Skin PAMPA results. Excellent agreement can 
be seen between Skin PAMPA results and in vivo human flux data, therefore the study concluded that Skin 
PAMPA is a good tool for ranking order of transdermal patches, and it can even estimate the human 
absorption rate with an acceptable precision. The detailed results of this study on transdermal patches will 
be published soon elsewhere. 
 
Figure 5. The permeated amount vs time profile of a marketed transdermal patch containing fentanyl. 
Conclusions 
In the past 2.5 years, Skin PAMPA as a bio-relevant artificial membrane based HT permeability model 
has been widely applied for the estimation of skin penetration. This paper has collected the most important 
publications, and grouped them based on the type of sample applied on the membrane.  The driving forces 
of the studies, the ways of application and the criteria of calculated parameter selection have been 
considered and suggestions for assay planning have been provided. It can be concluded, that the careful 
definition of study expectation, the proper design of the assay and the calculation of suitable parameters 
are crucial for satisfying results and for good prediction potential. 
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